Resultados de la búsqueda 791-800 of 10725 for monoclonal antibody

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...

  2. Colitis ulcerosa - Síntomas y causas - Mayo Clinic

    Kaplan GG. Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Relacionado.

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation ...

  4. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...

  5. Ensayos clínicos - Neurología

    The purpose of this study is to determine the prevalence, diagnostic accuracy and predictors of antinueronal antibody positivity in serum and cerebrospinal ...

  6. Hematología - Ensayos clínicos

    ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. Chemotherapy Alone or Chemotherapy Plus Radiation ...

  7. Programa de tumores cerebrales - Ensayos clínicos

    This randomized phase III trial compares memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing neurocognitive ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to evaluate whether profiling aggressive tumors for molecular alterations, together with drug testing in patient-derived 3D ...

  9. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...

  10. Investigación muestra que el nuevo tratamiento puede retrasar la progresión del cáncer en pacientes con mieloma múltiple latente de alto riesgo - Red de noticias de Mayo Clinic

    Resultados de un estudio clínico de Fase 3, publicado en New England Journal of Medicine, demostraron que el daratumumab, un anticuerpo monoclonal que se ...